Morpholine derivatives, pharmaceutical compositions and use
Abstract
Abstract Compounds are disclosed of formula (I): ##STR1## wherein R 1 and R 2 are the same or different and are C 1-6 alkyl or C 3-6 alkenyl; or --NR 1 R 2 forms a 5-membered (optionally containing an oxygen atom adjacent to the nitrogen) or a 6-membered ring, which ring optionally contains one unit of unsaturation and which is unsubstituted or substituted by hydroxy, oxo, optionally substituted methylidene, --COR 3 (where R 6 represents C 1-6 alkyl, OR 4 or --NHR 4 , and R 4 represents hydrogen, C 1-6 alkyl, aryl, ar(C 1-6 )alkyl) or ═NOR 5 (where R 5 represents C 1-6 alkyl); X represents a direct bond, --CH 2 -- or --CH 2 O--; Ar represents a substituted phenyl moiety; and physiologically acceptable salts thereof. The compounds are indicated as useful for the treatment of pain and cerebral ischaemia. Processes and intermediates for their preparation and pharmaceutical compositions containing them are also disclosed.
Inventors
- 👤 David I. C. Scopes
- 👤 David E. Bays
Bibliographic Details
Claims Analysis
Total Claims: 9References Cited (Backward Citations)
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1993-05-07 | 1993-11-06 | 1994-05-08 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1997-05-07 | 1997-11-06 | 1998-05-08 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2001-05-07 | 2001-11-06 | 2002-05-08 | $7700.00 | Window Closed / Lapsed |